Literature DB >> 29149920

Gastrointestinal and Hepatic Disease in the Inflammatory Myopathies.

Chiranjeevi Gadiparthi1, Amneet Hans2, Kyle Potts2, Mohammad K Ismail3.   

Abstract

Although muscle weakness is the pathognomonic feature of idiopathic inflammatory myopathies, systemic organ involvement is not uncommon. The gastrointestinal and hepatic manifestations are well known. Oropharyngeal dysphagia is the most common gastrointestinal symptom and can be severe. Gastric and small intestinal motility disorders, including chronic intestinal pseudo-obstruction, celiac disease, and inflammatory bowel disease have been described. Comprehensive cancer screening is warranted soon after the diagnosis of inflammatory myopathies due to high risk of occult malignancies. Elevated aminotransferases may suggest muscular injury rather than hepatic dysfunction. Knowledge regarding systemic involvement of inflammatory myopathies can assist in timely diagnosis of these complex disorders.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Corticosteroids; Creatine kinase; Dermatomyositis; Inclusion body myositis; Oropharyngeal dysphagia; Polymyositis

Mesh:

Year:  2018        PMID: 29149920     DOI: 10.1016/j.rdc.2017.09.006

Source DB:  PubMed          Journal:  Rheum Dis Clin North Am        ISSN: 0889-857X            Impact factor:   2.670


  4 in total

Review 1.  Juvenile dermatomyositis: advances in clinical presentation, myositis-specific antibodies and treatment.

Authors:  Jian-Qiang Wu; Mei-Ping Lu; Ann M Reed
Journal:  World J Pediatr       Date:  2019-09-26       Impact factor: 2.764

2.  Dysphagia as the Presenting Symptom for Inclusion Body Myositis.

Authors:  Marcus Juan Esteban; Darine Kassar; Osvaldo Padilla; Richard McCallum
Journal:  J Investig Med High Impact Case Rep       Date:  2021 Jan-Dec

3.  Application of Refined Nursing Combined with Comprehensive Treatment of Traditional Chinese and Western Medicine in Gastrointestinal Dysfunction after Tumor Operation.

Authors:  Hongqing Su; Yuexian Wen; Dandan Kang
Journal:  Evid Based Complement Alternat Med       Date:  2022-07-20       Impact factor: 2.650

Review 4.  Current Classification and Management of Inflammatory Myopathies.

Authors:  Jens Schmidt
Journal:  J Neuromuscul Dis       Date:  2018
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.